Should a patient with high oxygen requirements be started on a non‑rebreather mask (NRM) immediately, and what monitoring and escalation steps are recommended?

Starting a Patient with High Oxygen Requirements on NRM Immediately

Yes, a non-rebreather mask (NRM) at 15 L/min should be started immediately for patients with high oxygen requirements, specifically when SpO2 is below 85%, but this requires immediate senior review, arterial blood gas (ABG) monitoring within 1 hour, and readiness to escalate to non-invasive ventilation (NIV) or intubation if targets are not achieved. 1

Initial Assessment and Device Selection

The BTS guideline provides clear thresholds for when to initiate NRM:

• SpO2 <85%: Start with reservoir mask (NRM) at 15 L/min immediately 1
• SpO2 ≥85%: Begin with nasal cannulae (2-6 L/min) or simple face mask (5-10 L/min), then escalate if needed 1

Target saturation is 94-98% for patients without risk of hypercapnic respiratory failure 1

Critical Monitoring Requirements

When NRM is initiated, you must implement the following monitoring protocol:

Within the First Hour:

• Obtain ABG or earlobe blood gases within 60 minutes of starting NRM 1
• Measure respiratory rate and heart rate (tachypnea and tachycardia are more sensitive indicators than cyanosis) 1
• Continuous pulse oximetry monitoring
• Immediate senior medical staff assessment 1

Blood Gas Interpretation:

If ABG shows respiratory acidosis (pH <7.35 and PaCO2 >6.0 kPa), seek immediate senior review and consider NIV or ICU transfer 1

Escalation Algorithm

The decision tree proceeds as follows:

1. If target saturation (94-98%) achieved on NRM:

   • Titrate down to nasal cannulae or simple face mask once stabilized 1
   • Recheck ABG at 30-60 minutes after any adjustment 1

2. If target saturation NOT achieved on NRM:

   • Seek immediate senior/specialist review 1
   • Consider high-flow nasal cannula (HFNC) as alternative 1
   • Prepare for NIV or invasive ventilation 1

3. If patient deteriorates (rising NEWS score, increasing breathlessness, falling consciousness):

   • Immediate senior review
   • Consider NIV/ICU 1

Critical Pitfalls to Avoid

The Low-Flow NRM Trap:

Never use NRM with oxygen flow <10 L/min - this is a dangerous error. Research demonstrates that inadequate flow rates (<6-10 L/min) with NRM can cause CO2 rebreathing and lead to CO2 narcosis, particularly in COPD patients 2. The reservoir bag collapses with inadequate flow, defeating the purpose of the device. Always use 15 L/min with NRM 1, 2.

Prolonged NRM Use:

Evidence suggests that NRM use >2 hours in respiratory failure from pulmonary disease increases mortality (HR 1.3) 3. This underscores the importance of:

• Early senior review
• Timely escalation decisions
• Not using NRM as a "holding pattern" when more advanced support is needed

Special Population: COPD/Hypercapnic Risk

For patients with known COPD or risk factors for hypercapnia:

• Initial target is 88-92% pending ABG results 1
• However, in critical illness (sepsis, shock, major trauma), even COPD patients should initially receive NRM at 15 L/min targeting 94-98% until ABG results available 1
• Adjust target to 88-92% only if ABG confirms hypercapnia 1
• Consider Venturi masks (24-28%) or low-flow nasal cannulae (1-2 L/min) as safer alternatives once stabilized 2

Alternative Considerations

High-flow nasal cannula (HFNC) should be considered as an alternative to NRM in acute respiratory failure without hypercapnia 1. Recent evidence shows HFNC may be equivalent to NRM in COVID-19 respiratory failure with similar oxygenation improvement and outcomes 4.

Documentation Requirements

Ensure oxygen therapy is:

• Prescribed on the drug chart with target saturation range 1
• Documented with flow rate and device type
• Monitored with track-and-trigger systems (NEWS score) 1

The key principle: NRM at 15 L/min is appropriate for severe hypoxemia (SpO2 <85%), but it is a temporizing measure requiring urgent assessment, close monitoring, and readiness to escalate within 1-2 hours if the patient fails to improve.